Vineti, Inc., and Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ:
CYRXW) announced a commercial partnership designed to extend
end-to-end delivery of cell therapies and gene therapies to a
growing number of patients as the industry continues to scale.
Pairing Vineti’s supply chain orchestration (SCO)
platform
with Cryoport’s integrated
temperature-controlled capabilities and near real-time monitoring
will
provide an end-to-end solution for
advanced therapies, supporting the assurance of improved drug
product quality and patient safety. Vineti and Cryoport
together seek to leverage both of their commercial and clinical
phase experiences and insights from serving biopharma customers.
Together, the Vineti-Cryoport solution will seek to provide
biopharmaceutical developers with a pre-integrated SCO and
temperature logistics system that will offer digital, optimized
end-to-end traceability and control. With Vineti’s platform being
deployed in more than 300 clinical centers world-wide within the
next year, and Cryoport serving more than 400 clinical trials and
three commercialized therapies, the collaboration between the two
companies provides a broad-based global
solution.
Vineti’s supply chain orchestration (SCO) platform, the only
independent digital solution serving both clinical and commercial
advanced therapy products, will help clients ensure that there is
tight, automated management for each personalized drug product
across the entire supply chain. The Vineti platform delivers
digital Chain of Identity and Chain of Custody for regenerative
therapies, providing essential patient safety and regulatory
compliance for the most complex supply chain in the history of
medicine.
Cryoport, the world's leading temperature-controlled solutions
company serving the life sciences industry, will provide its
logistics solutions for clinical and commercial advanced therapy
products. Cryoport's suite of unique temperature-controlled
logistics solutions include its Cryoport Express® Shippers,
SmartPak II™ Condition Monitoring System, Cryoportal™ Logistics
Management Platform and its signature 24/7/365 logistics support
with intervention capability. These unparalleled capabilities
enable users to monitor their shipments and track the conditions,
location and courier handling of their biological commodities in
transit around the clock and to deploy intervention capability to
mitigate any potential logistics risks.
“Cryoport provides a range of powerful temperature-controlled
logistics solutions to the cell and gene therapy market, and its
team is constantly demonstrating a strong commitment to continuous
improvement to keep pace with the remarkable scientific and medical
progress in the field,” said Amy DuRoss, CEO and Co-Founder,
Vineti. “We are proud to be partnering with Cryoport to support
both clinical-phase and commercial customers, achieving efficiency
and optimization on behalf of the patients they serve.”
Jerrell Shelton, CEO of Cryoport commented, “Collaborating with
a leading-edge company like Vineti, which was co-founded by GE and
the Mayo Clinic, underscores Cryoport’s expanding reach within this
rapidly growing market. We are working constantly to secure
valuable collaborations that expand our ecosystem of
temperature-controlled solutions for the regenerative medicine
market. As the regenerative medicine market matures, the demands of
cell and gene therapy developers are becoming increasingly complex
and we are committed to enhancing our offerings with collaborations
such as this one with Vineti, the industry-leading supply chain
orchestration (SCO) platform, to better serve the life sciences and
bring on new clients.”
About VinetiVineti is the first commercial,
configurable cloud-based platform to expand patient access to
life-saving cell and gene therapies. Vineti was co-founded by GE
and the Mayo Clinic to solve the key challenges that patients,
medical providers, biopharmaceutical companies and regulators face
in the delivery and commercialization of individualized therapies.
Now a fully independent company, Vineti offers a digital platform
of record to integrate logistics, manufacturing and clinical data
for personalized therapies. The Vineti platform supports the full
continuum of patient-specific therapies, including cancer vaccines
and autologous and allogeneic therapies. The company is expanding
rapidly, and the Vineti platform will be in use in hundreds of
leading medical centers worldwide in 2019, on behalf of multiple
biopharmaceutical partners. In 2019, the World Economic Forum
selected Vineti as a global Technology Pioneer.
About Cryoport, Inc.Cryoport is the life
sciences industry's most trusted global provider of
temperature-controlled logistics solutions for
temperature-sensitive life sciences commodities, serving the
biopharmaceutical market with leading-edge logistics solutions for
biologic materials, such as regenerative medicine, including
immunotherapies, stem cells and CAR T-cells. Cryoport also provides
a range of bioservices to the life sciences industry, including
biostorage for biological specimens, materials and samples.
Cryoport's solutions are used by points-of-care, CRO's, central
laboratories, pharmaceutical companies, manufacturers, university
researchers et al; as well as the reproductive medicine market,
primarily in IVF and surrogacy; and the animal health market,
primarily in the areas of vaccines and reproduction. Cryoport's
proprietary Cryoport Express® Shippers, Cryoportal® Logistics
Management Platform, leading-edge SmartPak II™ Condition Monitoring
System and geo-sensing technology, paired with unparalleled cold
chain logistics expertise and 24/7 client support, make Cryoport
the end-to-end cold chain logistics partner that the industry
trusts. Cryoport is dedicated to: simplifying global cold chain
logistics through innovative technology, unmatched monitoring and
data capture and support, including consulting; delivering the most
advanced temperature-controlled logistics solutions for the life
sciences industry; and providing vital information that provides
peace of mind throughout the life of each logistics process.
For more information, visit www.cryoport.com. Sign up to
follow @cryoport on Twitter at www.twitter.com/cryoport.
Forward Looking
StatementsStatements in this news release which are not
purely historical, including statements regarding Cryoport, Inc.’s
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. It is important to note that the Company’s
actual results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, risks and
uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the
Company’s cash flow, market acceptance risks, and technical
development risks. The Company’s business could be affected by a
number of other factors, including the risk factors listed from
time to time in the Company’s SEC reports including, but not
limited to, the Company’s 10-K for the year ended December 31, 2018
filed with the SEC. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this
press release. Cryoport, Inc. disclaims any obligation, and does
not undertake to update or revise any forward-looking statements in
this press release.
Vineti Contact DetailsJoseph SalernoDirector,
PR and Scientific CommunicationsHDMZ,
Inc.joseph.salerno@hdmz.com
Cryoport Contact DetailsTodd Fromer/Elizabeth
Barkertfromer@kcsa.com/ebarker@kcsa.comP: 1 212-896-1203
CryoPort (NASDAQ:CYRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
CryoPort (NASDAQ:CYRX)
Historical Stock Chart
From Sep 2023 to Sep 2024